- Cellectar Biosciences (CLRB, Financial) to report Q1 2025 financial results on May 13, 2025, at 8:30 AM ET.
- The company will host a conference call accessible via toll-free number 1-800-717-1738 (Conference ID: 53983) and webcast.
- A replay of the presentation will be available on the company's Investor Relations website.
Cellectar Biosciences (CLRB), a late-stage clinical biopharmaceutical company, is set to announce its first quarter 2025 financial results on Tuesday, May 13, 2025, at 8:30 AM Eastern Time. Investors and interested parties can join the conference call via the toll-free number 1-800-717-1738 using Conference ID 53983, or they can access the live webcast through the company's website.
Specializing in the discovery, development, and commercialization of cancer treatment drugs, Cellectar Biosciences aims to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform. This innovative approach is designed to enhance the targeting of cancer cells, thereby improving drug efficacy and minimizing off-target effects.
The company’s leading products include iopofosine I 131 and CLR 225, which are targeted at various solid tumors and conditions such as multiple myeloma and CNS lymphoma. Notably, iopofosine I 131 has received multiple designations from the FDA and EMA, underscoring its potential impact in the biopharmaceutical landscape.
For further details and updates, stakeholders are encouraged to visit Cellectar's Investor Relations website, where a replay of the financial presentation will also be available post-conference.
